Journey Medical (DERM) Cash from Financing Activities (2021 - 2026)

Journey Medical (DERM) has 6 years of Cash from Financing Activities data on file, last reported at $220000.0 in Q1 2026.

• Quarterly Cash from Financing Activities fell 93.88% year-over-year to $220000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.8 million (down 32.21% YoY) and the FY2025 annual result came in at $16.2 million, down 4.51% from the prior year.
• Cash from Financing Activities retreated to $220000.0 in Q1 2026, from $5.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $19.2 million in Q4 2023 to a low of -$13.1 million in Q2 2023.
• A 5-year average of $2.7 million and a median of $1.6 million in 2024 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities slumped 11890.99% — and 2024, when it soared 3048.08%.
• Tracing DERM's Cash from Financing Activities over 5 years: stood at $948000.0 in 2022, then soared by 1926.37% to $19.2 million in 2023, then slumped by 44.72% to $10.6 million in 2024, then plunged by 48.9% to $5.4 million in 2025, then slumped by 95.95% to $220000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $220000.0 (Q1 2026), $5.4 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.